Compare Ginkgo Bioworks Holdings Inc (DNA) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Ryanair Holdings plc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.41 (market cap $505.73M), while Ryanair Holdings plc trades at $59.56 (market cap $29.63B). The key difference: Ryanair Holdings plc is far larger — about 58.6× Ginkgo Bioworks Holdings Inc's market cap, and Ryanair Holdings plc pays a 1.51% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | RYAAY | |
|---|---|---|
Market Cap | $505.73M | $29.63B |
Sector | Health | Industrials |
52-Week High | $16.14 | $73.82 |
52-Week Low | $5.48 | $53.24 |
Enterprise Value | $607.68M | $26.61B |
Dividend Yield | — | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.
DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.
RYAAY trades at $60.63, up 1.88% today, but faces a bearish technical signal with support at $58. Fundamentally, it shows strong profitability with a 12.13% net margin and a reasonable P/E of 14.37. Recent Q1 2026 earnings beat expectations despite a 34% profit decline due to lower fares and higher fuel costs (Reuters, 2026-07-20). The company maintains a robust balance sheet with $3.96B in cash and announced a strategic AI partnership with Google Cloud to enhance operations.
The outlook is mixed; analyst consensus is bullish (62.5% buy ratings), citing long-term advantages from industry consolidation and a strong financial position. However, near-term risks include volatile fuel prices, competitive fare pressures, and geopolitical tensions affecting travel demand. The stock presents a value opportunity for patient investors, but requires monitoring of operational execution amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
